Series C funding sends Biofourmis to near-unicorn status
Add BT as a preferred source
Singapore
HOMEGROWN startup Biofourmis has raised US$100 million in a Series C equity round led by Softbank Vision Fund 2, catapulting the healthcare company to near-unicorn status in a matter of months.
The latest funding, which sources said has quadrupled Biofourmis' valuation from about US$200 million previously, comes despite a slowdown in healthcare investments in the Asia-Pacific over the first half of the year.
TRENDING NOW
Yeoh Pei Xien: YTL’s third-gen scion with a pastor’s heart
UOB CEO’s youngest child Grant Wee turns burnout into a wellness business
Keppel H1 net profit drops 59% to S$155 million on impairments, M1 deal fallout; shares fall 4%
Singtel explores Nasdaq-SGX dual listing for data centre arm Nxera, local data centre Reit
